Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 9, 2020
Daily News
June 9, 2020
- Nippon Shinyaku’s DMD Drug Gets Orphan Status in Europe
June 9, 2020
- Evrenzo Shows Non-Inferiority to Nesp in Non-Dialysis CKD Patients
June 9, 2020
- Takhzyro Shows Sustained Effect in Staving Off HAE Attacks
June 9, 2020
- LDP Study Group Calls for Postponing Off-Year Re-Pricing
June 9, 2020
- Stable Supply Debate Set to Heat Up in Japan, Scientific Societies to Select Key Drugs by June-End
June 9, 2020
- Big 3 Generic Firms Log 5.9% Sales Increase in FY2019, with Contraction in Overseas Business: Jiho Tally
June 9, 2020
- JPMA Urges Govt to Establish “Headquarters” for Infectious Disease Control Policy: Chief
June 9, 2020
- Bayer HIF-PH Inhibitor Molidustat Filed in Japan in Q1
June 9, 2020
- Japan Team to Develop Nafamostat Inhaler Formulation for COVID-19
June 9, 2020
- Fujifilm’s Avigan COVID-19 Trial Might Continue into July
June 9, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…